Turning wood waste into a sustainable industrial vanillin process via multi-enzyme cascades

The Challenge

Moving Beyond Petroleum-Based Vanillin

Vanillin is one of the world’s most sought-after aromatic compounds, essential to the food, cosmetic and pharmaceutical industries. However, approximately 85% of global vanillin is currently produced via petroleum-based chemical synthesis, raising significant sustainability concerns.

Lignin, a renewable byproduct of the paper industry and one of the most abundant sources of aromatic carbon on Earth, represents a massive opportunity for sustainable vanillin production. However, to make lignin-to-vanillin conversion industrially viable, robust biocatalysts with enhanced catalytic activity and operational stability are needed.

The Solution

In a joint effort between Zymvol and partners from the Smartbox and B-ligZymes projects, the consortium set out to create an enzyme cascade capable of converting 4-n-propylguaiacol extracted from processed lignin into a revalorized product fit for commercial use.

This project was divided into three phases:

Phase 1

From 4-n-propylguaiacol to Isoeugenol

The initial milestone centered on engineering an eugenol oxidase (EUGO), an enzyme capable of performing the conversion of 4-n-propylguaiacol into isoeugenol, to resolve the primary reaction step.

Naturally occurring EUGO is prone to generating excessive side-products while operating at suboptimal speeds, creating a dual bottleneck that hinders high-yield synthesis. To solve this, Zymvol applied its computational enzyme optimization platform (Zymevolver) directly onto EUGO5X —a highly stable, 5-fold thermostable mutant previously developed by partners at the University of Groningen (RUG). Combining targeted in silico mutations with this thermostable scaffold yielded significantly better variants than mutating the wild-type enzyme alone.

In just 1 month of computational modeling, Zymvol designed and selected 16 targeted variants for experimental validation at RUG. Out of these 16 variants, 6 were active, and 5 outperformed the baseline enzyme.

Results & Impact

• • 96% product specificity improvement
    Computational mutations successfully minimized side-product formation, ensuring high chemoselectivity toward the desired intermediate (isoeugenol).
  • 34x increase in catalytic activity
    The best-performing variant demonstrated a 34-fold activity increase over the wild-type enzyme (and a 10-fold increase over the EUGO5X thermostable baseline).
  • Accelerated engineering timeframe
    The entire computational design phase took only 1 month and required screening just 16 physical mutants to identify top performers, drastically reducing lab iteration time.
  • Scalable biotransformation
    The lead enzyme successfully produced isoeugenol at scale, proving highly effective both as an isolated enzyme and in whole-cell systems.

Phase 2

From Isoeugenol to Vanillin

During this second phase, the consortium decided to focus on engineering NOV1, a dioxygenase enzyme capable of performing the conversion of isoeugenol into vanillin in single-step biocatalysis without the need for coenzymes.

A total of 35 variants were designed on the basis of the structural analysis of the NOV1 enzyme, in silico dockings, comparative structural alignments, and computation-based design, constructed and examined for activity toward the isoeugenol substrate.

Among these, project partners were able to shortlist its most promising candidate: the S283F variant.

Results & Impact

• >99% conversion efficiency
  The team achieved near-total conversion of isoeugenol to vanillin within 24 hours in enzymatic reactions.

• 4x improvement in oxygen-binding efficiency
  A critical advancement for industrial processes where oxygen levels are often a limiting factor.

• Superior substrate tolerance
  The variant successfully converted isoeugenol concentrations up to 100 mM—far surpassing current standard systems (10-20 mM).

• 20x operational stability
  Structural optimizations resulted in a 20-fold increase in stability and a 2x increase in turnover rate for isoeugenol.

• Scalable whole-cell catalysis
  High efficiency (>99%) was maintained using whole-cell catalysis, significantly reducing purification costs and supporting industrial scalability.

Phase 3

Boosting performance with distal mutations

Following the success of the initial enzyme design, the next phase set out to maximize the enzyme’s operational stability and the catalytic constant by looking beyond the active site.

To achieve this, our team used Zymspot technology to identify 62 distal mutations located more than 10 Å from the active site. By targeting these specific regions, we were able to attain performance gains that are typically impossible to find through traditional random mutagenesis.

Results & Impact

• 40x operational stability
  Mapping distal mutations allowed us to extend the enzyme’s operational life by 40-fold, a critical factor for long-term industrial cycles.

• 10x activity increase
  Advanced DNA shuffling of the top 6 identified positions resulted in final variants with up to 10x the activity of the wild-type.
• Efficiency vs. random screening
  While a parallel lab campaign of 3,000 random variants yielded only one hit (with lower activity than our starting point), our targeted mutagenesis study of just 41 single-point mutants yielded 9 superior hits.

This Sucess Story summarizes the results presented in original research papers published in Nature, Biochemistry, Journal of Biotechnology and Advanced Synthesis & Catalysis, featuring participation of scientists from Zymvol and from the European Projects Smartbox and B-ligZymes. In collaboration with: